Forest Services
Introduction: Keytruda’s Role in Cancer Immunotherapy
Keytruda (pembrolizumab) is a monoclonal antibody approved by the FDA in 2014 initially for melanoma and subsequently for over 20 cancer types, including non-small cell lung cancer (NSCLC) (FDA.gov, 2024). It functions as an immune checkpoint inhibitor targeting the programmed cell death protein 1 (PD-1) receptor on T-cells, thereby enhancing anti-tumour immune responses by preventing tumour-mediated immune evasion. India, facing a projected cancer incidence of 1.7 million new cases by 2025 (ICMR 2023), has seen growing demand for Keytruda. However, the proliferation of counterfeit versions, estimated to comprise 15% of oncology drugs in circulation (WHO 2023), threatens treatment efficacy and patient safety.
UPSC Relevance
- GS Paper 2: Health - Drug regulation, immunotherapy, counterfeit medicines
- GS Paper 3: Economy - Pharmaceutical market, patent laws, healthcare expenditure
- Essay: Public health challenges in India including counterfeit drugs and regulatory reforms
Pharmacological Mechanism of Keytruda
Keytruda is a humanized IgG4 monoclonal antibody that binds to the PD-1 receptor on activated T-cells, blocking its interaction with ligands PD-L1 and PD-L2 expressed on tumour cells and antigen-presenting cells. This blockade prevents the inhibitory signal that dampens T-cell activity, restoring cytotoxic T-cell function and enabling immune-mediated tumour cell destruction. Clinical trials under the KEYNOTE series demonstrated that Keytruda improves 5-year survival rates by up to 30% in NSCLC patients compared to chemotherapy (NEJM 2023).
- Targets PD-1 receptor on T-cells to inhibit immune checkpoint pathway
- Restores T-cell mediated immune surveillance against tumours
- Approved for melanoma, NSCLC, head and neck cancers, among others
- Improves long-term survival outcomes in multiple cancer types
Regulatory Framework Governing Keytruda in India
The Drugs and Cosmetics Act, 1940 (Sections 18, 27, 28) regulates drug approval and prohibits manufacture and sale of spurious drugs. The Drugs and Cosmetics Rules, 1945 (Rule 122E) mandates submission of clinical trial data for new drugs including biologics. The Drugs Controller General of India (DCGI), under the Central Drugs Standard Control Organization (CDSCO), is the apex authority responsible for approval and monitoring of Keytruda’s import, manufacture, and distribution in India. The Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954 restricts misleading claims about drug efficacy, critical to prevent false advertising of counterfeit products.
- DCGI approves biologics like Keytruda after rigorous clinical data evaluation
- Indian Patent Act, 1970 Section 3(d) restricts patenting of minor modifications, affecting biologic drug patents (Novartis AG v. Union of India, 2013)
- CDSCO issued 12 advisories in 2023 warning against counterfeit immunotherapy drugs including Keytruda (CDSCO Annual Report 2023)
- Enforcement challenges remain due to fragmented supply chains and lack of biologics-specific traceability
Economic Dimensions of Keytruda and Counterfeit Drugs
The global immunotherapy market was valued at approximately USD 100 billion in 2023, with Keytruda capturing over 20% market share (IQVIA 2023). India’s oncology drug market is projected to grow at a CAGR of 12% to reach USD 3.5 billion by 2025 (Frost & Sullivan). The average cost per cycle of genuine Keytruda in India ranges between INR 4-6 lakhs (Indian Express, 2024), making it inaccessible to many patients and incentivizing counterfeit drug circulation. Counterfeit oncology drugs cause economic losses exceeding USD 200 million annually in India (WHO 2023), undermining public health and imposing additional costs on healthcare systems.
- High cost of genuine Keytruda drives demand for cheaper counterfeit versions
- Counterfeit drugs priced 40-60% lower but lack efficacy and safety guarantees
- Government increased National Cancer Control Programme (NCCP) budget by 15% in 2023-24 to improve access to cancer drugs
- Economic losses from counterfeit drugs include treatment failures, increased morbidity, and legal liabilities
Comparison of Regulatory and Enforcement Mechanisms: India vs United States
| Aspect | United States (FDA) | India (CDSCO/DCGI) |
|---|---|---|
| Approval Process | Biologics License Application (BLA) with stringent clinical and manufacturing standards | Clinical trial data submission under Rule 122E; approval by DCGI |
| Counterfeit Detection | Advanced serialization and track-and-trace technology mandated; 85% reduction in counterfeit immunotherapy drugs (2018-2023) | Lacks nationwide biologics-specific track-and-trace system; delayed counterfeit detection |
| Enforcement | Robust regulatory inspections and penalties; public awareness campaigns | Fragmented enforcement; multiple advisories but limited field-level action |
| Patient Awareness | Regular public advisories and authentication tools for drug verification | Limited patient education on verifying drug authenticity |
Methods to Identify Genuine Keytruda from Counterfeits
Detecting counterfeit Keytruda requires multi-level verification due to its complex biologic nature. Genuine Keytruda packaging includes unique batch numbers, expiry dates, and manufacturer holograms traceable through CDSCO-approved serialization. Patients and healthcare providers should verify drugs via official channels and avoid unregulated suppliers. Laboratory assays such as ELISA and mass spectrometry can confirm molecular integrity but are not feasible for routine use. The DCGI’s 2023 advisories recommend vigilance on suspiciously low-priced drugs and reporting adverse events promptly.
- Check for CDSCO-approved packaging and holograms
- Verify batch numbers and expiry dates with manufacturer or CDSCO portals
- Avoid drugs priced significantly below market rates (40-60% lower signals counterfeit)
- Report suspected counterfeit drugs to DCGI and NCCP helplines
Significance and Way Forward
Keytruda has transformed cancer treatment by harnessing the immune system, improving survival outcomes across multiple cancers. However, counterfeit versions threaten patient safety and undermine public trust. Strengthening India’s regulatory framework requires implementing a nationwide biologics-specific track-and-trace system, enhancing real-time pharmacovigilance, and expanding patient and provider education on drug authentication. Increased budgetary allocation to NCCP should focus on subsidizing genuine immunotherapies and supporting enforcement agencies. Collaboration with WHO and adoption of global best practices, including serialization and digital verification, will reduce counterfeit prevalence and improve treatment efficacy.
- Implement biologics-specific serialization and track-and-trace nationwide
- Enhance DCGI and CDSCO capacity for field-level enforcement and rapid counterfeit detection
- Expand patient awareness campaigns on risks of counterfeit oncology drugs
- Increase subsidies and insurance coverage for genuine immunotherapies under NCCP
- Leverage international cooperation with WHO and FDA for technology transfer and regulatory harmonization
- Keytruda works by inhibiting the PD-L1 ligand on tumour cells to activate T-cells.
- The Drugs and Cosmetics Act, 1940 prohibits manufacture and sale of spurious drugs.
- The Indian Patent Act, 1970 allows patenting of all biologic drugs without exception.
Which of the above statements is/are correct?
- Counterfeit oncology drugs in India constitute about 15% of the market.
- Counterfeit Keytruda is typically priced higher than genuine versions.
- CDSCO has issued advisories to combat counterfeit immunotherapy drugs.
Which of the above statements is/are correct?
Jharkhand & JPSC Relevance
- JPSC Paper: Paper 2 – Health and Social Issues; Paper 3 – Economy and Public Administration
- Jharkhand Angle: Rising cancer incidence in Jharkhand increases demand for immunotherapy; counterfeit drugs pose local health risks due to weak supply chain enforcement.
- Mains Pointer: Highlight Jharkhand’s cancer burden, challenges in drug regulation at state level, and need for state-centre coordination in combating counterfeit drugs.
What is the primary mechanism of action of Keytruda?
Keytruda is a monoclonal antibody that blocks the PD-1 receptor on T-cells, preventing its interaction with PD-L1 and PD-L2 ligands, thereby restoring T-cell activity against tumour cells.
Which Indian law regulates the approval and prohibition of spurious drugs like counterfeit Keytruda?
The Drugs and Cosmetics Act, 1940 (Sections 18, 27, 28) governs drug approval and prohibits manufacture and sale of spurious or counterfeit drugs in India.
How does the Indian Patent Act affect biologic drugs like Keytruda?
Section 3(d) of the Indian Patent Act, 1970 restricts patenting of minor modifications, limiting patent protection for biologics. The Supreme Court judgment in Novartis AG v. Union of India (2013) upheld this interpretation.
What are the economic implications of counterfeit Keytruda in India?
Counterfeit Keytruda, priced 40-60% lower than genuine drugs, causes treatment failures, increased healthcare costs, and economic losses exceeding USD 200 million annually (WHO 2023).
What measures has the CDSCO taken to combat counterfeit immunotherapy drugs?
In 2023, CDSCO issued 12 advisories warning against counterfeit immunotherapy drugs, including Keytruda, and urged stakeholders to verify drug authenticity and report suspicious products.